Metabolite Profiling, Pharmacokinetics, and In Vitro Glucuronidation of Icaritin in Rats by Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry

Beibei Zhang, Xiaoli Chen, Rui Zhang, Fangfang Zheng, Shuzhang Du, and Xiaojian Zhang

Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China

Correspondence should be addressed to Shuzhang Du; dushuzhang911@163.com and Xiaojian Zhang; zhangxiaojian_yxb@163.com

Received 5 April 2017; Accepted 23 May 2017; Published 10 July 2017

Academic Editor: Filomena Conforti

Copyright © 2017 Beibei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Icaritin is a naturally bioactive flavonoid with several significant effects. This study aimed to clarify the metabolite profiling, pharmacokinetics, and glucuronidation of icaritin in rats. An ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS) assay was developed and validated for qualitative and quantitative analysis of icaritin. Glucuronidation rates were determined by incubating icaritin with uridine diphosphate glucuronic acid- (UDPGA-) supplemented microsomes. Kinetic parameters were derived by appropriate model fitting. A total of 30 metabolites were identified or tentatively characterized in rat biosamples based on retention times and characteristic fragmentations, following proposed metabolic pathway which was summarized. Additionally, the pharmacokinetics parameters were investigated after oral administration of icaritin. Moreover, icaritin glucuronidation in rat liver microsomes was efficient with CL\textsubscript{int} (the intrinsic clearance) values of 1.12 and 1.56 mL/min/mg for icaritin-3-O-glucuronide and icaritin-7-O-glucuronide, respectively. Similarly, the CL\textsubscript{int} values of icaritin-3-O-glucuronide and icaritin-7-O-glucuronide in rat intestine microsomes (RIM) were 1.45 and 0.86 mL/min/mg, respectively. Taken altogether, dehydrogenation at isopentenyl group and glycosylation and glucuronidation at the aglycone were main biotransformation process in vivo. The general tendency was that icaritin was transformed to glucuronide conjugates to be excreted from rat organism. In conclusion, these results would improve our understanding of metabolic fate of icaritin in vivo.

1. Introduction

Herba Epimedi, the dried aerial parts of Epimedium L. (Berberidaceae), are a widely used Chinese medicine for impotence, bone loss, and cardiovascular diseases [1–3]. Prenylflavonoids are reported to be a group of major active constituents present in Epimedium for the antioxidative stress, anti-inflammatory, antitumor, and antiosteoporosis activities [4–8]. Icaritin is the common aglycone with many biological effects, especially antiosteoporosis activities [5, 7]. Besides, icaritin could induce cell death in activated hepatic stellate cells through mitochondrial activated apoptosis and ameliorate the development of liver fibrosis in rats [9]. Meanwhile, icaritin is able to target androgen receptor and androgen receptor COOH-terminal truncated splice variants, to inhibit androgen receptor signaling and tumor growth with no apparent toxicity [10]. Additionally, icaritin has neuroprotective effects against MPP\textsuperscript{+}-induced toxicity in MES23.5 cells. IGF-I receptor mediated activation of PI3K/Akt and MEK/ERK1/2 pathways are involved in the neuroprotective effects of icaritin against MPP\textsuperscript{+}-induced neuronal damage [11]. Recently, icaritin had been shown as a potential agent for the treatment of systemic lupus erythematosus [12].

These biological activities above had stimulated increasing interests in the in vivo metabolism of icaritin or its related prenylflavonoids. Poor bioavailability of prenylated flavonoids results from their poor intrinsic permeation and transporter-mediated efflux by the human intestinal Caco-2 model and the perfused rat intestinal model [13]. Meanwhile, it is shown that Epimedium flavonoids could be hydrolyzed into secondary glycosides or aglycone by intestinal flora or enzymes, thereby enhancing their absorption and antiosteoporosis activity [14]. So far, numerous researches of total prenylflavonoids or individual flavonoid had been conducted in the fields of in vivo metabolites profiling, biliary excretion, and pharmacokinetics [15–19]. Generally, the in vivo
metabolism of *Herba Epimedii* extracts or its prenylflavonoids could easily be metabolized in gastrointestinal tract following deglycosylation reaction. Additionally, icaritin was easily metabolized into glucuronidation conjugates to be preferentially eliminated and excreted from rat organism [16, 18, 20]. Though the data on metabolic researches of icaritin abounds, its metabolic profile is not so clear. It is essential to systematically characterize the in vivo metabolites in order to better understand its mechanism of action. Hence, the present study aimed to conduct the metabolites screening, quantitative determination, and in vitro glucuronidation of icaritin.

Recently, liquid chromatography coupled with mass spectrometry (LC-MS) had been widely introduced to rapidly screen trace components in biological samples [21, 22]. In this study, icaritin-related metabolites were analyzed based on characteristic fragmentation by UPLC-MS after oral administration. Meanwhile, possible disposing pathway of icaritin was proposed. Furthermore, a UPLC-MS method was developed and applied to perform the pharmacokinetics of icaritin. Moreover, glucuronidation rates were determined by incubating icaritin with uridine diphosphate glucuronic acid- (UDPGA-) supplemented rat liver microsomes (RLM) and rat intestine microsomes (RIM). Kinetic parameters were derived by appropriate model fitting. Icaritin was subjected to significant hepatic and gastrointestinal glucuronidation.

2. Materials and Methods

2.1. Materials. Icaritin, epimedin C, icariside I, icariside II, and desmethylicaritin (purity > 98%) were purchased from Nanjing Jingzhu Medical Technology Co., Ltd. Uridine diphosphate glucuronic acid (UDPGA), magnesium chloride (MgCl₂), alamethicin, D-saccharic-1, and 4-lactone were provided from Sigma-Aldrich (St. Louis, MO). Rat liver microsomes (RLM) and rat intestine microsomes (RIM) were prepared in our laboratory based on the protocol [21]. HPLC grade methanol and acetonitrile were purchased from Dikma Scientific and Technology Co., Ltd. All other chemicals were of analytical grade.

2.2. Animals. Male Sprague-Dawley rats (180–220 g) were provided by Guangdong Medical Laboratory Animal Center. The rats were kept in an animal room at constant temperature (24 ± 2)°C and humidity (60 ± 5)% with 12 h of light/dark per day and free access to water and food. The animal protocols were approved and conducted in accordance with the guidelines of Laboratory Animal Ethics Committee of Zhengzhou University.

2.3. Samples Collection and Preparation for Qualitative Analysis. After the rats were fasted for 12 h with free access to water before experiments, icaritin dissolved in 0.3% sodium carboxymethyl cellulose solution was orally administrated to rats at a dose of 100 mg/kg. Blood samples were collected from external jugular vein into heparinized tubes and were separated by centrifuging at 13800g for 10 min at 4°C, respectively. Bile samples were collected and recorded during 0–24 h period after an abdominal incision anesthetized with 10% aqueous chloral hydrate. The urine and feces samples were collected separately during 0–24 h period after oral administration. Small intestinal samples were obtained after oral administration for 24 h. All blank samples were obtained in the same way.

Before experiments, all biosamples were stored at −20°C. In this work, solid phase extraction method was applied to pretreat all samples. Before use, C18 columns (3 cm³, 60 mg) were first preconditioned and equilibrated with 3 mL of methanol and 3 mL of water, respectively. Urine samples were evaporated and concentrated at 40°C under reduced pressure. Feces samples and small intestinal samples were dried in air and stirred into powder. And then they were treated with an ultrasonic bath for 30 min. The filtrate was combined and evaporated to dryness at 40°C in vacuum. The residue was reconstituted with water. Plasma, urine, bile, feces, and small intestinal samples were loaded on pretreated columns. The residue was reconstituted in 200 μL of 60% methanol and filtered through a 0.22 μm membrane until injection.

2.4. Samples Preparation for Quantitative Analysis. Plasma sample (200 μL) was treated with methanol (1.2 mL), after which the mixture was vortex-mixed for 30 s and centrifuged at 13800g for 10 min at 4°C. The supernatant was then transferred and evaporated to dryness using N₂ at room temperature. The residue was dissolved in 200 μL of 60% methanol and was then injected into the UPLC-MS system.

2.5. Preparation of Standard Solutions. Blank rat plasma was spiked with standard working solutions to achieve final concentration of icaritin of 2.0, 4.0, 16.0, 64.0, 128.0, 256.0, and 512.0 ng/mL. All reference standard solutions were stored at 4°C until use.

2.6. Glucuronidation Assay. Icaritin was incubated with RLM and RIM to determine the rates of glucuronidation as published references previously [23]. Briefly, the incubation mixture mainly contained 50 mM Tris-hydrochloric acid buffer (pH = 7.4), 0.88 mM MgCl₂, 22 μg/mL alamethicin, 4.4 mM saccharolactone, and 3.5 mM UDPGA. The reaction was terminated by adding ice-cold acetonitrile. The samples were vortexed and centrifuged at 13800g for 10 min. The supernatant was subjected to UPLC-MS analysis. All experiments were performed in triplicate.

2.7. UPLC-MS Conditions. UPLC was performed using an ACQUITY™ UPLC system (Waters, Milford, MA, USA). Separation was achieved on a Waters BEH C18 column (1.7 μm, 2.1 × 50 mm) maintained at 35°C. The mobile phase consisted of water (A) and acetonitrile (B) (both containing 0.1% formic acid), and the flow rate was 0.5 mL/min. The gradient elution program was as follows: 0 min, 15% B; 3 min 35% B; 7 min 60% B; 8 min 100% B. An aliquot of 4 μL sample was then injected into the UPLC-MS system.

The UPLC system was coupled to a Waters Xevo TQD (Waters, Milford, MA, USA) with electrospray ionization.
The operating parameters were as follows: capillary voltage, 2.5 kV (ESI+); sample cone voltage, 30.0 V; extraction cone voltage, 4.0 V; source temperature, 100°C; desolvation temperature, 300°C; and desolvation gas flow, 800 L/h. The method employed lock spray with leucine enkephalin (m/z 556.2771 in positive ion mode and m/z 554.2615 in negative ion mode) to ensure mass accuracy.

2.8. Pharmacokinetic Application. After fasting with free access to water for 12 h, icarin was given to rats as a dosage of 100 mg/kg. Plasma samples were then obtained at 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h after administration. For pharmacokinetic application, DAS 2.0 was used to calculate the pivotal pharmacokinetic parameters.

2.9. Enzymes Kinetic Evaluation. Serial concentrations of icarin (0.4–20 μM) were incubated with RLM and RIM to determine icarin glucuronidation rates. The kinetic models Michaelis-Menten equation and substrate inhibition equation were fitted to the data of metabolic rates versus substrate concentrations and displayed in (1) and (2), respectively. Appropriate models were selected by visual inspection of the Eadie-Hofstee plot [24]. Model fitting and parameter estimation were performed by Graphpad Prism V5 software (San Diego, CA).

The parameters were as follows. V is the formation rate of product. Vmax is the maximal velocity. Km is the Michaelis constant and [S] is the substrate concentration. Ks is the substrate inhibition constant. The intrinsic clearance (CLint) was derived by Vmax/Km for Michaelis-Menten and substrate inhibition models.

\[
V = \frac{V_{\text{max}} \times [S]}{K_m + [S]},
\]

\[
V = \frac{V_{\text{max}} \times [S]}{K_m + [S] (1 + [S]/K_s)}.
\]

3. Results

3.1. Fragment Pattern of Icariin. As had already been reported in the previous study [16], besides the typical adduct ion [M+Na]+ at m/z 391.1151 (C21H23O13Na) and [M+H]+ at m/z 369.1336 (C21H23O12), the ion at m/z 313.0714 (C17H13O6) in positive ion mode was considered as the characteristic fragment ion (see Figure S1a in the Supplementary Material available online at https://doi.org/10.1155/2017/1073607).

3.2. Screening of Metabolites. On the basis of MS/MS fragmentation pattern, the metabolites were deduced, clarifying the general metabolism in vivo. The extracted ion chromatograms (EICs) of prototype (M0) and metabolites (M1–M30) were shown in Figure 1, while the individual EICs of M1–M30 were exhibited in Figure S2. The UV, MS, and MS/MS data of M0–M30 were all exhibited in Table 1.

3.3. Structure Elucidation of Metabolites

M0 (Parent Drug). M0 (7.20 min, C21H23O12, −0.5 ppm) in biological samples was unambiguously identified by comparing with references.

M15 and M23 (Hydration of Isopentene Group). Based on the [M+H]+ ion at m/z 387.1445 (C21H23O12, 0.3 ppm) and [M−H]+ ion at m/z 385.1286 (C21H22O12), the molecular formula of M15 (4.34 min) and M23 (4.97 min) was determined as C21H22O12, with one H2O more than M0. The MS/MS spectrum of [M+H]+ ion (C21H23O12) showed predominant [M+H−H2O]+ ion at m/z 369.1343 and 313.0715 (Figure S1b), which indicated that M15 and M23 were the hydration products at isopentene group of icariin and agreed with previous study of icariin [18].

M25 (Demethylation of Flavonoid Aglycone). According to the [M+H]+ ion at m/z 355.1180 (C20H20O12, −0.6 ppm) and [M−H]+ ion at m/z 353.1036 (C20H19O12), the formula of M25 (5.08 min) was supposed as C20H20O12, with a methyl group less than M0. The MS/MS experiments (Figure S1c) showed a significant loss of neutral loss of C6H4 (56.0626 Da) from the ion at m/z 355.1180 to 299.0582 in positive ion mode or from the ion at m/z 353.1036 to 297.0373 in negative ion mode. Meanwhile, the demethylation position was purposed at 4’ position of B ring of flavonoid aglycone. Moreover, M25 was identified as desmethylcaritin by comparison of reference standard.

M30 (Dehydrogenation of Isopentene Group). The formula of M30 (6.36 min) was C20H18O6, with two hydrogens fewer than M0, based on the [M+H]+ ion at m/z 367.1180 (C21H19O6, −0.5 ppm) and [M−H]+ ion at m/z 365.1047 (C21H18O6). In MS/MS spectrum (Figure S1d), the ions at m/z 352.0948 and 313.0721 were attributed to obvious loss of CH3 (54.0470 Da) and C4H6 (54.0470 Da) group, respectively, which indicated that the dehydrogenation position was at isopentene group [18].

M27–M29 (Hydroxylation of Isopentene Group). From the [M+H]+ ion at m/z 385.1288 (C21H20O12, 0.3 ppm) and [M−H]+ ion at m/z 383.1175 (C21H19O12), the formulae of M27 (5.37 min, λmax 268 nm), M28 (5.54 min), and M29 (5.66 min) were speculated as C21H20O7, which was one oxygen more than M0. In (+) ESI-MS/MS spectrum (Figure S1e), the ion at m/z 385.1288 could lose a H2O and C4H4 group to produce the daughter ions at 367.1186 ([M+H−H2O]+) and 313.0715 ([M+H−C4H6]+), respectively. This illustrated that M27–M29 were tentatively characterized as the hydroxylated products of M0 at the isopentene group.

M14, M16, M17, M19, M20, and M21 (Glycosylation of Flavonoid Aglycone). M21 (4.88 min) was given a [M+H]+ ion at m/z 515.1927 (C27H31O10, 1.9 ppm) and [M−H]+ ion at m/z 513.1766 (C27H29O10) in full scan mass spectrum. The ion at m/z 515.1927 could easily yield the characteristic fragment ions at m/z 369.1340 and 313.0726 by subsequent loss of C4H4O3 and C4H4 (Figure S1f). So M21 could be the glycosylation product of M0 by adduct of rhamnose (C6H10O5, 146.0579 Da). Similarly, M17 (4.53 min, C27H30O11, 1.5 ppm)
Figure 1: EICs of all metabolites in rat biosamples after oral administration of icaritin. (a) Plasma; (b) urine; (c) bile; (d) feces; (e) intestine.
| Number | $t_R$ min | UV nm | [M + H]$^+$ | Error ppm | Formula | (+) ESI-MS/MS | (–) ESI-MS/MS | Sources | Characterization |
|--------|-----------|-------|-------------|------------|----------|---------------|---------------|---------|-----------------|
| M0$^*$ | 7.20      | 272   | 369.1336    | –0.5       | C$_{21}$H$_{39}$O$_6$ | 391.1152 369.1336<br>313.074 215.0748<br>281.0443 253.0485 | 367.1180 352.0941<br>309.0417 297.0999<br>281.0443 253.0485 | PUBFI | Icaritin |
| M1     | 2.48      | 270   | 721.1978    | –0.3       | C$_{23}$H$_{36}$O$_{18}$ | 543.1882 369.1345<br>313.0717<br>309.0417 297.0999<br>281.0443 253.0485 | 367.1194 | PUBI | Icaritin-di-O-gluA |
| M2     | 2.62      | 269   | 563.1768    | 0.5        | C$_{27}$H$_{30}$O$_{13}$ | 563.1768 387.1442<br>369.1332 313.0713 | 561.1608 385.1288<br>353.1025 119.0504<br>353.1025 119.0504 | UBI | Hydrated icaritin-O-gluA |
| M3     | 2.89      | 345   | 531.1511    | 1.5        | C$_{26}$H$_{26}$O$_{12}$ | 531.1511 355.1166<br>299.0576<br>353.1025 119.0506 | 529.1348 353.1025<br>353.1025 119.0506<br>353.1025 119.0506 | UBI | Desmethylcaritin-O-gluA |
| M4     | 3.15      | 341   | 561.1617    | 1.6        | C$_{27}$H$_{25}$O$_{13}$ | 561.1617 385.1301<br>367.1186 | 559.1458 383.1172<br>367.1186 175.0526<br>367.1186 175.0526 | UBI | Hydroxylated icaritin-O-gluA |
| M5     | 3.22      | 341   | 561.1613    | 0.9        | C$_{27}$H$_{25}$O$_{13}$ | 561.1613 385.1296 | 559.1458 383.1172<br>367.1186 175.0526<br>367.1186 175.0526 | UBI | Hydroxylated icaritin-O-gluA |
| M6     | 3.36      | 345   | 531.1503    | 0.0        | C$_{26}$H$_{26}$O$_{12}$ | 531.1503 355.1175<br>329.0741 314.0455<br>313.0715 | 529.1348 353.1025<br>353.1025 119.0506<br>353.1025 119.0506 | UBI | Desmethylcaritin-O-gluA |
| M7     | 3.41      | 341   | 561.1605    | –0.5       | C$_{27}$H$_{24}$O$_{13}$ | 561.1605 385.1295<br>313.0715 | 559.1460 383.1171<br>367.1196 | UBI | Hydroxylated icaritin-O-gluA |
| M8     | 3.46      | 270   | 721.1982    | 0.3        | C$_{31}$H$_{36}$O$_{18}$ | 721.1982 545.1662<br>369.1340 313.0717 | 719.1825 543.1521<br>367.1194 | UBI | Icaritin-di-O-gluA |
| M9     | 3.52      | 341   | 561.1608    | 0         | C$_{27}$H$_{25}$O$_{13}$ | 561.1608 385.1283 | 559.1454 383.1170<br>175.0526<br>175.0526 | UBI | Hydroxylated icaritin-O-gluA |
| M10    | 3.58      | 269   | 563.1761    | –0.7       | C$_{27}$H$_{30}$O$_{13}$ | 563.1761 387.1452<br>369.1350 313.0735 | 561.1605 385.1289 | UBI | Hydroxylated icaritin-O-gluA |
| Number | \( t_R \) min | UV nm | \([M + H]^+\) | Error ppm | Formula | (+) ESI-MS/MS | (−) ESI-MS/MS | Sources | Characterization |
|--------|-------------|------|-------------|-----------|---------|--------------|--------------|--------|-----------------|
| M11    | 3.74        | 341  | 561.1615    | 1.2       | \( C_{27}H_{24}O_{13} \) | 561.1615 385.1292 367.1186 | 559.1462 383.1175 | BI      | Hydroxylated icaritin-O-gluA |
| M12    | 4.29        | n.a. | 543.1501    | −0.4      | \( C_{27}H_{26}O_{12} \) | 543.1501 367.1189 | 541.1343 365.1034 351.0765 175.0221 113.0253 | I       | Dehydrogenated icaritin-O-gluA |
| M13    | 4.34        | 271  | 545.1663    | 0.7       | \( C_{27}H_{26}O_{12} \) | 567.1486 545.1663 369.1335 313.0716 | 543.1501 367.1188 352.0948 309.0408 297.0398 281.0498 821.2863 659.2331 | PUBFI   | Icaritin-O-gluA |
| M14\* | 4.40        | 270  | 823.3024    | −0.1      | \( C_{39}H_{50}O_{19} \) | 823.3024 369.1324 313.0721 | 821.2863 659.2331 367.1168 351.0867 385.1288 | I       | Epimedin C |
| M15    | 4.45        | 273  | 387.1440    | −1.0      | \( C_{21}H_{22}O_{7} \) | 387.1440 369.1338 313.0722 | 821.2863 659.2333 367.1165 351.0869 529.1705 367.1182 | I       | Hydrated icaritin |
| M16    | 4.49        | 270  | 823.3021    | −0.5      | \( C_{29}H_{50}O_{19} \) | 823.3021 369.1336 313.0725 | 821.2863 659.2333 367.1165 351.0869 529.1705 367.1182 | I       | Epimedin C isomer |
| M17\* | 4.53        | 270  | 531.1866    | 1.5       | \( C_{27}H_{30}O_{11} \) | 531.1866 369.1350 313.0718 | 352.0948 297.0395 253.0496 | FI      | Icariside I |
| M18    | 4.57        | 271  | 545.1661    | 0.4       | \( C_{27}H_{28}O_{12} \) | 545.1661 369.1346 313.0723 | 543.1503 367.1183 352.0945 297.0594 645.2168 367.1162 351.0863 323.0945 295.0595 659.2343 367.1165 | PUBFI   | Icaritin-O-gluA |
| M19    | 4.59        | 271  | 647.2349    | 1.4       | \( C_{28}H_{38}O_{14} \) | 669.2215 647.2349 515.1930 369.1346 313.0724 | 645.2168 367.1162 351.0863 323.0945 295.0595 659.2343 367.1165 | I       | Icaritin-rha-xyl |
| M20    | 4.61        | 270  | 661.2503    | 1.1       | \( C_{23}H_{45}O_{14} \) | 683.2326 661.2503 369.1339 313.0779 | 351.0865 295.0602 217.0499 | FI      | Icaritin-rha-rha |
| M21\* | 4.88        | 269  | 515.1927    | 1.9       | \( C_{27}H_{30}O_{10} \) | 537.1757 515.1927 369.1340 313.0726 | 513.1766 367.1157 352.0900 323.0910 295.0604 217.0498 | FI      | Icariside II |
| Number | t<sub>r</sub> (min) | UV (nm) | [M + H]<sup>+</sup> | Error (ppm) | Formula | (+) ESI-MS/MS | (–) ESI-MS/MS | Sources | Characterization |
|--------|-------------------|---------|---------------------|------------|----------|----------------|----------------|---------|------------------|
| M22    | 4.93              | 300     | 543.1500            | –0.6       | C<sub>27</sub>H<sub>26</sub>O<sub>12</sub> | 565.1453 543.1500 | 541.1345 365.1033 | BI      | Dehydrogenated icaritin-O-gluA |
| M23    | 4.97              | 273     | 387.1445            | 0.3        | C<sub>21</sub>H<sub>22</sub>O<sub>7</sub> | 387.1445 369.1343 313.0715 | 385.1286 | UFI | Hydrated icaritin |
| M24    | 5.02              | 300     | 543.1505            | 0.4        | C<sub>27</sub>H<sub>26</sub>O<sub>12</sub> | 543.1505 367.1134 313.0720 | 541.1346 365.1032 | BI | Dehydrogenated icaritin-O-gluA |
| M25<sup>#</sup> | 5.08             | 270     | 355.1180            | –0.6       | C<sub>20</sub>H<sub>18</sub>O<sub>6</sub> | 355.1180 299.0582 | 353.1036 309.0409 | UFI | Desmethylicaritin |
| M26    | 5.13              | 271     | 545.1664            | 0.9        | C<sub>27</sub>H<sub>26</sub>O<sub>12</sub> | 567.1540 545.1664 369.1343 313.0720 299.0585 | 543.1504 367.1180 297.0373 281.0481 | BI | Icaritin-O-gluA |
| M27    | 5.37              | 268     | 385.1288            | 0.3        | C<sub>21</sub>H<sub>25</sub>O<sub>7</sub> | 407.1136 385.1288 367.1186 313.0715 | 385.1175 365.1035 175.0226 | UFI | Hydroxylated icaritin |
| M28    | 5.54              | 268     | 385.1285            | –0.5       | C<sub>21</sub>H<sub>25</sub>O<sub>7</sub> | 385.1285 367.1181 313.0719 | 383.1170 365.1046 | UFI | Hydroxylated icaritin |
| M29    | 5.66              | n.a.    | 385.1290            | 0.9        | C<sub>21</sub>H<sub>25</sub>O<sub>7</sub> | 385.1290 367.1176 313.0712 | 383.1172 367.1043 175.0262 | UFI | Hydroxylated icaritin |
| M30    | 6.36              | 272     | 367.1180            | –0.5       | C<sub>21</sub>H<sub>18</sub>O<sub>6</sub> | 367.1180 352.0948 313.0721 297.0395 253.0496 | 365.1047 351.0765 175.0223 113.0250 | FI | Dehydrogenated icaritin |

<sup>#</sup> means that the metabolites are exactly identified with reference standards.
was the glucose conjugate of M0, while M19 (4.59 min, C_{32}H_{39}O_{44}, 1.4 ppm) and M20 (4.61 min, C_{33}H_{43}O_{44}, 1.1 ppm) were the xylose and rhamnose glycosylation derivatives of M21, respectively. M14, M17, and M21 were identified as epimedin C, icariside I, and icariside II, respectively.

M14 (4.40 min, λ_max 270 nm, C_{39}H_{32}O_{19}, −0.1 ppm) and M16 (4.49 min, λ_max 270 nm, C_{39}H_{32}O_{19}, −0.5 ppm) both with the formula of C_{39}H_{32}O_{19} (Figure S1g) were tentatively characterized as the glucose glycosylation conjugate of M20. These glycosylation reactions were the same as the metabolism of epimedin C in rats reported in reference [Liu et al., 2011]. By comparing with references, M14, M17, and M21 were identified as epimedin C, icariside I, and icariside II, respectively. And the MS/MS spectra of M17, M19, and M20 were shown in Figures S1h–S1l, respectively.

M1, M8, M13, M18, and M26 (Glucuronidation of Flavonoid Aglycone). In full scan mass spectrum, M13 (4.34 min), M18 (4.57 min), and M26 (5.10 min) all exhibited the [M + H]^+ ion at m/z 545.1663 (C_{27}H_{26}O_{12}, 0.7 ppm) and [M − H]^- ion at m/z 543.1501 (C_{27}H_{26}O_{12}) with a formula of C_{27}H_{26}O_{12} of 176.0325 Da larger than M0. The MS/MS spectrum (Figure S1k) displayed an obvious loss of C_176 and O_8 ppm, which suggested an existing glucuronic acid of M27. The MS/MS spectra of M16 (4.49 min, C_{39}H_{32}O_{18}, −0.3 ppm) and M26 (3.45 min, C_{39}H_{32}O_{18}, 0.3 ppm) (Figure S1l) were characterized as glucuronidation derivatives based on two molecules of C_{39}H_{32}O_{18}, fragment larger than M0.

Similarly, M2 (2.62 min, λ_max 269 nm, C_{21}H_{20}O_{13}, 0.5 ppm) and M10 (3.57 min, λ_max 269 nm, C_{21}H_{20}O_{13}, −0.7 ppm) with the MS/MS spectrum shown in Figure S1m were tentatively characterized as the glucuronidation products of M15 and M23. M3 (2.89 min, λ_max 345 nm, C_{26}H_{26}O_{12}, 1.5 ppm) and M6 (3.36 min, λ_max 345 nm, C_{26}H_{26}O_{12}, 0 ppm) were characterized as glucuronidation conjugate of M25. The MS/MS spectrum of M3 and M6 was exhibited in Figure S1n. Meanwhile, M4 (3.16 min, λ_max 341 nm, C_{27}H_{28}O_{13}, 1.6 ppm), M5 (3.21 min, λ_max 341 nm, C_{27}H_{28}O_{13}, 0.9 ppm), M7 (3.40 min, λ_max 341 nm, C_{27}H_{28}O_{13}, −0.5 ppm), M9 (3.50 min, λ_max 341 nm, C_{27}H_{28}O_{13}, 0 ppm), and M11 (3.74 min, λ_max 341 nm, C_{27}H_{28}O_{13}, 1.2 ppm) were regarded as glucuronidation derivatives of M27–M29 and their MS/MS spectrum was displayed in Figure S1o. M12 (4.29 min, not available λ_max, C_{27}H_{28}O_{13}, −0.4 ppm), M22 (4.94 min, λ_max 300 nm, C_{27}H_{28}O_{13}, −0.6 ppm), and M24 (5.02 min, λ_max 300 nm, C_{27}H_{28}O_{13}, 0.4 ppm) were tentatively identified as glucuronidation conjugates of M30. And their MS/MS spectrum was shown in Figure S1p.

3.4. Method Validation. The method was validated for specificity, linearity, extraction recovery, matrix effects, precision, accuracy, and stability according to the US Food Drug Administration guidelines for bioanalytical method validation [25].

Specificity was determined by comparing the chromatograms obtained for six blank plasma samples, blank plasma samples spiked with standard solutions at LLOQ concentrations, and drug plasma samples obtained 4 h after oral administration. As shown in Figure S3, no interference peaks were detected at the retention times of icaritin.

The LOD and LOQ were calculated as 3-fold and 10-fold of the ratio of signal-to-noise, respectively. The LLOQ was defined as the lowest concentration in the calibration curve with accuracy of 80–120% and precision of 20%. Calibration curves were acquired by plotting peak area (y) versus respective plasma concentrations (x) using a 1/x^2 weighting factor and linear least-squares regression analysis. A series of standard solutions were used to generate calibration curve. The correlation coefficients (r^2) of calibration curves were greater than 0.9926 within 2.0–512.0 ng/mL and LLOQ was 2.0 ng/mL. The regression equations, correlation coefficients, and LLOQ were shown in Table S1.

The experiments to evaluate matrix effect and recovery were conducted by the protocol [26]. According to the protocol, the peak areas from QC samples at three concentrations were defined as A1; those from extracted control plasma reconstituted with standard solutions at 4.0, 64.0, and 256.0 ng/mL were A2. The responses of icaritin found by direct injection of the corresponding pure reference standards at three QC levels were A3. The matrix effect and recovery were calculated as follows: matrix effect (%) = A2/A1×100%. Recovery (%) = A1/A2×100%. The results (as shown in Table S2) illustrated that matrix effect was between 89.1% and 113.5%, and the recovery was from 96.3% to 102.7%.

The accuracy and inter/intraday precision of the method were evaluated by determining six replicates of QC samples on three consecutive days. The measured concentrations of QC samples were determined with a calibration curve obtained on the same day. Relative error and relative standard deviation were used to describe accuracy and inter/intraday precision, respectively. They both should not exceed 15%. As exhibited in Table S3, the intraday and interday precision were less than 13.2% and 10.2%, respectively, while the intraday and interday precision of LLOQ were no more than 17.4% and 15.6%, respectively.

Stability of icaritin in rat plasma was assessed under different conditions at three concentration levels, including extracted samples for 12 h at room temperature, kept at −20°C for 60 h, three cycles of freezing at −20°C and thawing at 25°C, and plasma sample at room temperature for 8 h. Each was compared by three QC replicates of the same concentration with a calibration curve in the same day. The RE was within 13.8% and RSD was less than 11.3%. Stability results (Table S4) indicated that icaritin was stable under different storage conditions.

3.5. Pharmacokinetics Application. The mean concentration-time profiles of these bioactive components were illustrated in Figure 2. The main pharmacokinetic parameters were illustrated in Table 2. In this study, C_{max} was (294.5± 22.7) ng/mL.
Figure 2: Concentration-time curve of icaritin in rat plasma after oral administration.

Table 2: Pharmacokinetic parameters of icaritin in rat plasma after oral administration.

| Parameters          | 100 mg/kg |
|---------------------|-----------|
| $T_{\text{max}}$ (h) | 5.3 ± 1.1 |
| $C_{\text{max}}$ (ng/mL) | 294.5 ± 22.7 |
| $t_{1/2}$ (h)      | 8.3 ± 1.0 |
| AUC$_{0-\infty}$ (ng·h/mL) | 3048.5 ± 289.0 |
| AUC$_{0-\infty}$ (ng·h/mL) | 3145.0 ± 302.3 |
| MRT$_{0-\infty}$ (h) | 9.6 ± 1.1 |
| MRT$_{0-\infty}$ (h) | 10.9 ± 1.3 |

when $T_{\text{max}}$ was (5.3 ± 1.1) h after oral administration. The area under the concentration-time curve (AUC$_{0-\infty}$) and mean residence time (MRT$_{0-\infty}$) were (3145.0 ± 302.3) ng·h/mL and (10.9 ± 1.3) h, respectively. The results illustrated that icaritin had a poor absorption after oral administration. The reason may be that icaritin entered the small intestine to undergo phase I and phase II metabolism by intestinal flora, especially the glycosylation and glucuronidation conjugates.

3.6. Glucuronidation of Icaritin in RLM and RIM. Due to lack of reference standard, quantification of icaritin glucuronide was based on the standard curve of the parent compound (icaritin) according to the assumption that parent compound and its glucuronide have closely similar UV absorbance maxima [27–29]. The detection wavelength of icaritin and icaritin glucuronides was 270 nm. The linear range of icaritin was 0.02–20 μM, with LOD (S/N = 3–5) and LOQ (S/N = 8–10) of 0.01 and 0.02 μM, respectively. The acceptable linear correlation ($Y = 12149X$) was confirmed by correlation coefficients ($r^2$) of 0.9994. The accuracy and precision of the intraday and interday error were both less than 3.4%. There were no matrix effects observed and no other sample preparation performed except those mentioned in the manuscript.

Kinetic profiling revealed that formation of icaritin-3-O-glucuronide (M13) and icaritin-7-O-glucuronide (M18) in RLM was well modeled by the substrate inhibition equation (Figure 3(a)), whereas they followed the classical Michaelis-Menten kinetics in RIM (Figure 3(b)). In contrast, the glucuronide formation of M13 (4.06 nmol/min/mg) and M18 (2.39 nmol/min/mg) in RLM was similar as well as M13 (11.88 nmol/min/mg) and M18 (8.23 nmol/min/mg) in RIM. Icaritin glucuronidation in RLM was efficient ($K_m$ values of 3.62 and 1.53 μM, respectively). Similarly, the $K_m$ values of M13 and M18 in RIM were 8.22 and 9.56 μM, respectively. In addition, $K_i$ values of M13 and M18 in RLM were 11.31 and 17.07 μM, respectively. The detailed parameters of M13 and M18 were listed in Table 3.

4. Discussion

Normally, only the prototypes or metabolites in blood with a high enough exposure in target organs for a finite period of time are considered as potential effective components for therapeutic benefits [30]. In this study, M0, M1, and M13 were the main xenobiotics in plasma (Figure 1(a)), which may be the potential in vivo effective components directly. After circulation, M2, M5, M13, M23, and M28 were passed out with the urine (Figure 1(b)).

Due to poor oral bioavailability, several components were limited to be absorbed in blood. But they could influence intestinal dysfunction to exert efficacy by their prototypes, secondary metabolites, or finally the aglycone in intestinal
Table 3: Kinetic parameters of icaritin glucuronidation by RLM and RIM (mean ± SD).

| Protein source | Metabolite | \( V_{\text{max}} \) (nmol/min/mg) | \( K_m \) (\( \mu \text{M} \)) | \( K_i \) (\( \mu \text{M} \)) | \( \text{CL}_{\text{int}} \) (mL/min/mg) | Model  |
|----------------|------------|---------------------------------|----------------|----------------|---------------------------------|-------|
| RLM M13        | 4.06 ± 0.70| 3.62 ± 0.99                     | 11.31 ± 3.51 | 1.12 ± 0.36    | SI                              |
| M13            | 2.39 ± 0.26| 1.53 ± 0.34                     | 17.07 ± 4.38 | 1.56 ± 0.38    | SI                              |
| RIM M13        | 11.88 ± 0.60| 8.22 ± 0.92                     | N.A.          | 1.45 ± 0.18    | MM                              |
| M18            | 8.23 ± 0.63| 9.56 ± 1.51                     | N.A.          | 0.86 ± 0.15    | MM                              |

Note: SI, substrate inhibition model; MM, Michaelis-Menten model; N.A., not available.

Figure 3: Kinetic profiles for glucuronidation of icaritin by various types of microsomes. (a) Pooled rat liver microsomes (RLM); (b) pooled rat intestine microsomes (RIM). In each panel, the insert figure showed the corresponding Eadie-Hofstee plot.

Based on the metabolite profiles, the metabolic pathways of icaritin were proposed and shown in Figure 4(a), and the metabolic sites were shown in Figure 4(b). In summary, icaritin was hard to be absorbed into the rat blood. In small intestine, icaritin could form flavonoid glycoside by the sequential glycosylation metabolism. Meanwhile, icaritin could easily conjugate with a glucuronic acid to form phase II metabolites in liver, which indicated that the biliary clearance was one of the major routes of excretion. Phase I metabolism of icaritin mainly included demethylation, dehydrogenation, and hydration. The general tendency was that the saponins were metabolized and transformed into the high polar metabolites to be eliminated and excreted from the rat organism.

5. Conclusion

As a result, a total of 30 metabolites were identified or tentatively characterized based on the retention time behaviors and fragmentation patterns. Dehydrogenation at isopentenyl group and glycosylation and glucuronidation at the flavonoid aglycone were the main biotransformation process of icaritin in vivo. Meanwhile, a validated method was successfully applied to a pharmacokinetic study. Moreover, icaritin glucuronidation in RLM was efficient with \( \text{CL}_{\text{int}} \) values of 1.12 and 1.56 mL/min/mg for M13 and M18, respectively. Similarly, the \( \text{CL}_{\text{int}} \) values of M13 and M18 in RIM were 1.45 and 0.86 mL/min/mg, respectively. Taken altogether, this
study could provide an experimental basis to understand the metabolic fate of icarin in rat.

**Conflicts of Interest**

The authors have declared no conflicts of interest.

**Authors’ Contributions**

Beibei Zhang, Shuzhang Du, and Xiaojian Zhang conceived and designed the experiments. Beibei Zhang and Xiaoli Chen performed the experiments. Beibei Zhang and Rui Zhang contributed analytic tools. Beibei Zhang and Fangfang Zheng

**Figure 4:** The proposed metabolic pathway (a) and metabolic sites (b) of icarin in rats.
References

[1] Editorial Committee of Pharmacopoeia of Ministry of Health PR China, The Pharmacopoeia of People’s Republic of China (Part 1), Chemical Industry Press, Beijing, China, 2015.

[2] H. Ma, X. He, Y. Yang, M. Li, D. Hao, and Z. Jia, “The genus Epimedium: an ethnopharmacological and phytochemical review,” Journal of Ethnopharmacology, vol. 134, no. 3, pp. 519–541, 2011.

[3] F. Xu, Y. Ding, Y. Guo et al., “Anti-osteoporosis effect of Epimedium via an estrogen-like mechanism based on a systems-level approach,” Journal of Ethnopharmacology, vol. 177, pp. 148–160, 2016.

[4] J. Zhou, J. Wu, X. Chen et al., “Icarin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions,” International Immunopharmacology, vol. 11, no. 7, pp. 890–898, 2011.

[5] S.-H. Chen, M. Lei, X.-H. Xie et al., “PLGA/TCP composite scaffold incorporating bioactive phytomolecule icaritin for enhancement of bone defect repair in rabbits,” Acta Biomaterialia, vol. 9, no. 5, pp. 6711–6722, 2013.

[6] X. Lai, Y. Ye, C. Sun et al., “Icaritin exhibits anti-inflammatory effects in the mouse peritoneal macrophages and peritonitis model,” International Immunopharmacology, vol. 16, no. 1, pp. 41–49, 2013.

[7] S. Peng, G. Zhang, B.-T. Zhang et al., “The beneficial effect of Icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats,” Bone, vol. 55, no. 1, pp. 230–240, 2013.

[8] S. W. Lei, G. Cui, G. P. H. Leung et al., “Icaritin protects against oxidative stress-induced injury in cardiac H9c2 cells via Akt/Nrf2/HO-1 and calcium signalling pathways,” Journal of Functional Foods, vol. 18, pp. 213–223, 2015.

[9] J. Li, P. Liu, R. Zhang et al., “Icaritin induces cell death in activated hepatic stellate cells through mitochondrial activated apoptosis and ameliorates the development of liver fibrosis in rats,” Journal of Ethnopharmacology, vol. 137, no. 1, pp. 714–723, 2011.

[10] F. Sun, I. R. Indran, Z. W. Zhang et al., “A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants,” Carcinogenesis, vol. 36, no. 7, pp. 757–768, 2015.

[11] M.-C. Jiang, X.-H. Chen, X. Zhao, X.-J. Zhang, and W.-F. Chen, “Involvement of IGF-1 receptor signaling pathway in the neuroprotective effects of Icaritin against MPP+-induced toxicity in MES23.5 cells,” European Journal of Pharmacology, vol. 786, pp. 53–59, 2016.

[12] J. Liao, Y. Liu, H. Wu et al., “The role of icaritin in regulating Foxp3/IL17a balance in systemic lupus erythematosus and its effects on the treatment of MRL/lpr mice,” Clinical Immunology, vol. 162, pp. 74–83, 2016.

[13] Y. Chen, Y. H. Zhao, X. B. Jia, and M. Hu, “Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo),” Pharmaceutical Research, vol. 25, no. 9, pp. 2190–2199, 2008.

[14] J. Zhou, Y. H. Ma, Z. Zhou, Y. Chen, Y. Wang, and X. Gao, “Special section on drug metabolism and the microbiome intestinal absorption and metabolism of epimedium flavonoids in osteoporosis rats,” Drug Metabolism and Disposition, vol. 43, no. 10, pp. 1590–1600, 2015.

[15] Y.-T. Wu, C.-W. Lin, L.-C. Lin, A. W. Chiu, K.-K. Chen, and T.-H. Tsai, “Analysis of biliary excretion of icaritin in rats,” Journal of Agricultural and Food Chemistry, vol. 58, no. 18, pp. 9905–9911, 2010.

[16] H. Zhao, M. Fan, L. Fan, J. Sun, and D. Guo, “Liquid chromatography-tandem mass spectrometry analysis of metabolites in rats after administration of prenyllavonoids from Epimediums,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 878, no. 15–16, pp. 1113–1124, 2010.

[17] Q. Chang, G.-N. Wang, Y. Li, L. Zhang, C. You, and Y. Zheng, “Oral absorption and excretion of icaritin, an aglycone and also active metabolite of prenyllavonoids from the Chinese medicine Herba Epimedi in rats,” Phytotherapy, vol. 19, no. 11, pp. 1024–1028, 2012.

[18] Q. Qian, S.-L. Li, E. Sun et al., “Metabolite profiles of icarin in rat plasma by ultra-fast liquid chromatography coupled to triple-quadrupole/time-of-flight mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 66, pp. 392–398, 2012.

[19] Y. Jin, C.-S. Wu, J.-L. Zhang, and Y.-F. Li, “A new strategy for the discovery of epimedium metabolites using high-performance liquid chromatography with high resolution mass spectrometry,” Analytica Chimica Acta, vol. 768, no. 1, pp. 111–117, 2013.

[20] L. Cui, F. Xu, J. Jiang et al., “Identification of metabolites of epimedin A in rats using UPLC/Q-TOF-MS,” Chromatographia, vol. 77, no. 17–18, pp. 1223–1234, 2014.

[21] H. Liu, H. Sun, D. Lu et al., “Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence,” Xenobiotica, vol. 44, no. 8, pp. 696–707, 2014.

[22] F. Li, Y. Tan, H. Chen et al., “Identification of schisandrin as a vascular endothelium protective component in YiQiFuMai powder injection using HUVECs binding and HPLC-DAD-Q-TOF-MS/MS analysis,” Journal of Pharmaceutical Sciences, vol. 129, no. 1, pp. 1–8, 2015.

[23] D. Lu, Z. Ma, T. Zhang, X. Zhang, and B. Wu, “Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1,” Xenobiotica, vol. 46, no. 1, pp. 1–13, 2016.

[24] J. M. Hutzler and T. S. Tracy, “Atypical kinetic profiles in drug metabolism reactions,” Drug Metabolism and Disposition, vol. 30, no. 4, pp. 355–362, 2002.

[25] US FDA, Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), http://www.fda.gov/cder/guidance, 2001.

[26] B. K. Matuszewski, M. L. Constanzer, and C. M. Chavez-Eng, “Matrix effect in quantitative LCMSMS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations,” Analytical Chemistry, vol. 70, no. 5, pp. 882–889, 1998.

[27] J. Troberg, E. Järvinen, G. Ge, L. Yang, and M. Finel, “UGT1A10 is a high activity and important extrahepatic enzyme: why has its role in intestinal glucuronidation been frequently underestimated?” Molecular Pharmaceutics, Ahead of Print, 2016.

[28] D. Lu, H. Liu, W. Ye, Y. Wang, and B. Wu, “Structure- and isoform-specific glucuronidation of six curcumin analogs,” Xenobiotica, pp. 1–10, 2016.
[29] H. Sun, H. Wang, H. Liu, X. Zhang, and B. Wu, “Glucuronidation of capsaicin by liver microsomes and expressed UGT enzymes: reaction kinetics, contribution of individual enzymes and marked species differences,” Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 10, pp. 1325–1336, 2014.

[30] X. Wang, “Studies on serum pharmacochemistry of traditional Chinese medicine,” World Science And Technology/Modernization of Traditional Chinese Medicine, vol. 4, no. 2, pp. 1–4, 2002.

[31] R. Zhang, S. Gilbert, X. Yao et al., “Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses,” Pharmacology Research Perspectives, vol. 3, article e00118, no. 2, 2015.

[32] B. Wu, K. Kulkarni, S. Basu, S. Zhang, and M. Hu, “First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics,” Journal of Pharmaceutical Sciences, vol. 100, no. 9, pp. 3655–3681, 2011.

[33] B. Wu, D. Dong, M. Hu, and S. Zhang, “Quantitative prediction of glucuronidation in humans using the in vitro-in vivo extrapolation approach,” Current Topics in Medicinal Chemistry, vol. 13, no. 11, pp. 1343–1352, 2013.